1. Home
  2. UCAR vs TVRD Comparison

UCAR vs TVRD Comparison

Compare UCAR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.35

Market Cap

35.5M

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.84

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
TVRD
Founded
2013
2017
Country
China
United States
Employees
N/A
12
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
34.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
TVRD
Price
$1.35
$2.84
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$50.00
$29.50
AVG Volume (30 Days)
480.7K
45.6K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$2.75
52 Week High
$4.98
$43.65

Technical Indicators

Market Signals
Indicator
UCAR
TVRD
Relative Strength Index (RSI) 46.86 34.12
Support Level $1.14 N/A
Resistance Level $1.68 $4.32
Average True Range (ATR) 0.11 0.29
MACD -0.01 -0.10
Stochastic Oscillator 22.77 2.34

Price Performance

Historical Comparison
UCAR
TVRD

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: